Investor Relations Dashboard

Mauna Kea Technologies (Euronext: MKEA, FR0010609263; OTCQX: MKEAY), the inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization.

We've recently released our First Quarter 2017 sales results, please click on the button below to hear Sacha Loiseau, Founder, CEO, John Soto, COO and Benoit Jacheet, CFO review the financial results, recent operational accomplishments and key priorities. 

2016 Full Year Financial Results  Click to hear CEO interview

You can stay up to date on all the latest investor news by signing up to our newsletter  

 

Latest News

  • March 23, 2017  
    Mauna Kea Technologies Reports Full Year 2016 Financial Results and Highlights 2017 Key Priorities
    Read the press release.

  • March 23, 2017  
    Mauna Kea Technologies confirms its eligibility to the French PEA-PME investment vehicles for 2017/2018
    Read the press release.


Stock Information

Share Price Information

 

Click here to view more..

 

Documentation

 

Financial Agenda

  • Jul. 25, 2017 - 2017 First-Half Sales
  • May 3, 2017 - Annual General Meeting
  • Apr. 25, 2017 - 2017 First-Quarter Sales
  • Mar. 23, 2017 - 2016 Full-Year Results

 

 

Corporate Governance

The Board of directors of Mauna kea Technologies comprises of an international multi-disciplinary group of experts and industry leaders.